ZA200402939B - Combinations comprising a selective cyclooxygenase-2 inhibitor. - Google Patents
Combinations comprising a selective cyclooxygenase-2 inhibitor. Download PDFInfo
- Publication number
- ZA200402939B ZA200402939B ZA200402939A ZA200402939A ZA200402939B ZA 200402939 B ZA200402939 B ZA 200402939B ZA 200402939 A ZA200402939 A ZA 200402939A ZA 200402939 A ZA200402939 A ZA 200402939A ZA 200402939 B ZA200402939 B ZA 200402939B
- Authority
- ZA
- South Africa
- Prior art keywords
- inhibitor
- pharmaceutically acceptable
- fluoro
- methyl
- treatment
- Prior art date
Links
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 title claims description 53
- 229940093444 Cyclooxygenase 2 inhibitor Drugs 0.000 title claims description 13
- 150000003839 salts Chemical class 0.000 claims description 61
- 238000011282 treatment Methods 0.000 claims description 57
- 125000001153 fluoro group Chemical group F* 0.000 claims description 49
- 229910052739 hydrogen Inorganic materials 0.000 claims description 46
- 239000001257 hydrogen Substances 0.000 claims description 46
- 150000001875 compounds Chemical class 0.000 claims description 45
- 229940111134 coxibs Drugs 0.000 claims description 40
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 30
- 239000002525 vasculotropin inhibitor Substances 0.000 claims description 27
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 26
- -1 chloro, methyl Chemical group 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 22
- AADVCYNFEREWOS-UHFFFAOYSA-N (+)-DDM Natural products C=CC=CC(C)C(OC(N)=O)C(C)C(O)C(C)CC(C)=CC(C)C(O)C(C)C=CC(O)CC1OC(=O)C(C)C(O)C1C AADVCYNFEREWOS-UHFFFAOYSA-N 0.000 claims description 21
- 208000029742 colonic neoplasm Diseases 0.000 claims description 21
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 20
- 210000001072 colon Anatomy 0.000 claims description 20
- 150000002148 esters Chemical class 0.000 claims description 20
- 230000002265 prevention Effects 0.000 claims description 20
- 206010009944 Colon cancer Diseases 0.000 claims description 19
- 230000003902 lesion Effects 0.000 claims description 19
- 230000003211 malignant effect Effects 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 18
- 239000000651 prodrug Substances 0.000 claims description 18
- 229940002612 prodrug Drugs 0.000 claims description 18
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 17
- KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 claims description 17
- AADVCYNFEREWOS-OBRABYBLSA-N Discodermolide Chemical compound C=C\C=C/[C@H](C)[C@H](OC(N)=O)[C@@H](C)[C@H](O)[C@@H](C)C\C(C)=C/[C@H](C)[C@@H](O)[C@@H](C)\C=C/[C@@H](O)C[C@@H]1OC(=O)[C@H](C)[C@@H](O)[C@H]1C AADVCYNFEREWOS-OBRABYBLSA-N 0.000 claims description 16
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 claims description 15
- 150000003883 epothilone derivatives Chemical class 0.000 claims description 15
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims description 14
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 14
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 claims description 14
- 108091008605 VEGF receptors Proteins 0.000 claims description 12
- 229930013356 epothilone Natural products 0.000 claims description 11
- 150000002431 hydrogen Chemical class 0.000 claims description 11
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims description 10
- 239000012453 solvate Substances 0.000 claims description 10
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical group C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 claims description 10
- 229960005499 (+)-discodermolide Drugs 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 229930012538 Paclitaxel Natural products 0.000 claims description 8
- 229940123237 Taxane Drugs 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 8
- 229960001592 paclitaxel Drugs 0.000 claims description 8
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 8
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 8
- 229960001338 colchicine Drugs 0.000 claims description 7
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 7
- 102000029749 Microtubule Human genes 0.000 claims description 6
- 108091022875 Microtubule Proteins 0.000 claims description 6
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 6
- 229960003668 docetaxel Drugs 0.000 claims description 6
- 230000002452 interceptive effect Effects 0.000 claims description 6
- 210000004688 microtubule Anatomy 0.000 claims description 6
- 230000002062 proliferating effect Effects 0.000 claims description 6
- 229940122803 Vinca alkaloid Drugs 0.000 claims description 5
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 claims description 5
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 claims description 5
- 229960001237 podophyllotoxin Drugs 0.000 claims description 5
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 5
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims description 5
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 102000009465 Growth Factor Receptors Human genes 0.000 claims description 3
- 108010009202 Growth Factor Receptors Proteins 0.000 claims description 3
- 230000008472 epithelial growth Effects 0.000 claims description 3
- 201000001514 prostate carcinoma Diseases 0.000 claims description 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 31
- 229940121647 egfr inhibitor Drugs 0.000 description 21
- 208000037062 Polyps Diseases 0.000 description 20
- 238000000034 method Methods 0.000 description 20
- 201000011510 cancer Diseases 0.000 description 16
- 230000036210 malignancy Effects 0.000 description 16
- 239000002552 dosage form Substances 0.000 description 15
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 11
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 9
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- XRYJULCDUUATMC-CYBMUJFWSA-N 4-[4-[[(1r)-1-phenylethyl]amino]-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenol Chemical compound N([C@H](C)C=1C=CC=CC=1)C(C=1C=2)=NC=NC=1NC=2C1=CC=C(O)C=C1 XRYJULCDUUATMC-CYBMUJFWSA-N 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 238000002648 combination therapy Methods 0.000 description 7
- 208000032177 Intestinal Polyps Diseases 0.000 description 6
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 6
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 4
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 4
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 229960003048 vinblastine Drugs 0.000 description 4
- WHOWNXIYXLWMGJ-UHFFFAOYSA-N 1-(pyridin-4-ylmethyl)phthalazine Chemical class N=1N=CC2=CC=CC=C2C=1CC1=CC=NC=C1 WHOWNXIYXLWMGJ-UHFFFAOYSA-N 0.000 description 3
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical class N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 3
- 108010037464 Cyclooxygenase 1 Proteins 0.000 description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010029113 Neovascularisation Diseases 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 3
- 125000005907 alkyl ester group Chemical group 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000003679 cervix uteri Anatomy 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 201000010536 head and neck cancer Diseases 0.000 description 3
- 208000014829 head and neck neoplasm Diseases 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 3
- 208000015768 polyposis Diseases 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 238000010972 statistical evaluation Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229960001278 teniposide Drugs 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 210000003932 urinary bladder Anatomy 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 3
- 229960002110 vincristine sulfate Drugs 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 241001050985 Disco Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 229960002986 dinoprostone Drugs 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 231100000304 hepatotoxicity Toxicity 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 150000003951 lactams Chemical class 0.000 description 2
- 230000007056 liver toxicity Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 2
- KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 description 2
- 229960004982 vinblastine sulfate Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 2
- 229960002066 vinorelbine Drugs 0.000 description 2
- KYARBIJYVGJZLB-UHFFFAOYSA-N 7-amino-4-hydroxy-2-naphthalenesulfonic acid Chemical compound OC1=CC(S(O)(=O)=O)=CC2=CC(N)=CC=C21 KYARBIJYVGJZLB-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- BEFZAMRWPCMWFJ-JRBBLYSQSA-N Epothilone C Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C=C\C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C BEFZAMRWPCMWFJ-JRBBLYSQSA-N 0.000 description 1
- XOZIUKBZLSUILX-SDMHVBBESA-N Epothilone D Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C(/C)=C/C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C XOZIUKBZLSUILX-SDMHVBBESA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 1
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- BEFZAMRWPCMWFJ-UHFFFAOYSA-N desoxyepothilone A Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC=CCC1C(C)=CC1=CSC(C)=N1 BEFZAMRWPCMWFJ-UHFFFAOYSA-N 0.000 description 1
- XOZIUKBZLSUILX-UHFFFAOYSA-N desoxyepothilone B Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC(C)=CCC1C(C)=CC1=CSC(C)=N1 XOZIUKBZLSUILX-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical class CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000000773 effect on pain Effects 0.000 description 1
- BEFZAMRWPCMWFJ-QJKGZULSSA-N epothilone C Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 BEFZAMRWPCMWFJ-QJKGZULSSA-N 0.000 description 1
- XOZIUKBZLSUILX-GIQCAXHBSA-N epothilone D Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-GIQCAXHBSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 229960000752 etoposide phosphate Drugs 0.000 description 1
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000002411 histidines Chemical class 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Combinations comprising a selective Cyclooxygenase-2 Inhibitor
The invention relates to a method of preventing or treating pre-malignant colon lesions (e.g. . polyps) and colon cancer, as well as other malignancies in a warm-blooded animal, especially a mammal, particularly a human, with a combination of pharmaceutical agents which comprises (a) a selective cyclooxygenase-2 inhibitor (“COX-2 inhibitor”) and (b) at least one compound selected from the group consisting of a microtubule interfering agent ("MIA™), a non-covalent epithelial growth factor receptor tyrosine protein kinase inhibitor (“EGFR inhibitor”) and a vascular endothelial growth factor receptor tyrosine kinase inhibitor (“VEGF inhibitor”). The invention further relates to pharmaceutical compositions comprising (a) COX-2 inhibitor and (b) at least one compound selected from the group consisting of an
MIA, an EGFR inhibitor and a VEGF inhibitor and (c) a pharmaceutically acceptable carrier.
The present invention further relates to a commercial package or product comprising (a) a pharmaceutical formulation of a COX-2 inhibitor and (b) at least one pharmaceutical formulation of a compound selected from the group consisting of an MIA, an EGFR inhibitor and an VEGF inhibitor for simultaneous, concurrent, separate or sequential use.
Non-steroidal antiinflammatory agents are known to block prostaglandin synthesis by inhibition of the enzyme cyclooxygenase. Cyclooxygenase is now known to comprise a constitutive isoform, cyclooxygenase-1 (“COX-1"), and an inducible isoform, cyclo- oxygenase-2 (“COX-2").
COX-2 inhibitors are known in the art as compounds that selectively inhibit cyclooxygenase- 2 without appreciable inhibition of cyclooxygenase-1. Methods of measuring the inhibition of cyclooxygenase-1 and —2 are known in the art.
Without being bound to any particular theory, it is postulated that the improved efficacy seen with a combination comprisng a COX-2 inhibitor and a VEGF inhibitor is based on the following findings. Cyclooxygenase-2 is expressed in endothelial cells during tumor neovascularization as well as in epithelial cancer cells present in human colon, breast, prostate and lung tissues. It is known that prostaglandin E2 or 12 generated by COX-2 induces VEGF receptors in the endothelial cells and accelerates angiogenesis. The formation of new blood vessels to provide nutrients is a major requirement for the growth of solid tumors. VEGF inhibitors also inhibit neovascularization by inhibiton of vascular endothelial growth factor receptors. Thus, the combination of agents synergistically inhibit neovascularization and tumor activity by both reducing the number of vascular endothelial growth factor receptors and by inhibiting those receptors that are present. ’
Of the known COX-2 inhibitors, the 5-alkyl substituted 2-arylaminophenylacetic acids and derivatives are especially useful in the present invention. Such compounds, their use, preparation and galenical formulations comprising such compounds are disclosed in U.S.
Patent No. 6,291,523, which is here in corporated by reference.
Useful COX-2 inhibitors disclosed in U.S. Patent No. 6,291,523 are described by formula
R 1G CH,COOH
R, Rs
Ry R,
R, wherein R is methyl or ethyl;
R; is chloro or fluoro;
R: is hydrogen or fluoro;
Rs is hydrogen, fluoro, chloro, methyl, ethyl, methoxy, ethoxy or hydroxy;
R, is hydrogen or fluoro; and
Rs is chloro, fluoro, trifluoromethyl or methyl; pharmaceutically acceptable salts or solvates thereof; and pharmaceutically acceptable prodrug esters thereof.
A particular embodiment of the invention relates to the compounds of formula | wherein R is methyl or ethyl; R, is chloro or fluoro; R; is hydrogen; R, is hydrogen, fiuoro, chloro, methyl . or hydroxy; R, is hydrogen; and Rs is chloro, fluoro or methyl; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable prodrug esters thereof. :
A preferred embodiment relates to the compounds of formula | wherein R is methyl or ethyl;
R, is fluoro; R; is hydrogen; Rj; is hydrogen, fluoro or hydroxy; R, is hydrogen; and Rs is chloro; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable prodrug , esters thereof.
Another preferred embodiment of the invention relates to compound of formula | wherein R is ethyl or methyl; R; is fluoro; R; is hydrogen or fluoro; Rj is hydrogen, fluoro, ethoxy or hydroxy; R, is hydrogen or fluoro; and Rs is chloro, fluoro or methyl; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable prodrug esters thereof.
Further preferred are said compounds wherein R is methyl or ethyl; R, is fluoro; R,-R, are hydrogen or fluoro; and Rs is chloro or fluoro; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable prodrug esters thereof.
A further embodiment of the invention relates to the compounds of formula | wherein R is methyl or ethyl; R, is fluoro; R; is fluoro; Rj is hydrogen, ethoxy or hydroxy; R, is fluoro; and
Rs is fluoro; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable prodrug esters thereof.
Another preferred embodiment of the invention relates to the compounds of formula wherein R is methyl; R, is fluoro; R; is hydrogen; R; is hydrogen or fluoro; R, is hydrogen; and Rs is chloro; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable prodrug esters thereof.
Particular embodiments of the invention relate to compounds of formula (a) wherein R is methyl; R; is fluoro; R; is hydrogen; Rj is hydrogen; R, is hydrogen; and Rs is chloro; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable prodrug esters thereof; ) (b) wherein R is methyl; R, is fluoro; R; is hydrogen; Rjis fluoro; R, is hydrogen; and
Rs is chloro; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable ‘ prodrug esters thereof;
(c) wherein Ris ethyl; R, is fluoro; R; is fluoro; Rj is hydrogen; R, is fiuoro; and Rj is fluoro; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable prodrug esters thereof; and (d) wherein Ris ethyl; R, is chloro; R; is hydrogen; Rj is chloro; R, is hydrogen; and )
Rs is methyl; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable prodrug esters thereof.
The general definitions used herein have the following meaning within the scope of the present invention.
Pharmaceutically acceptable prodrug esters are ester derivatives which are convertible by solvolysis or under physiological conditions to the free carboxylic acids of formula l. Such esters are e.g. lower alkyl esters (such as the methyl or ethyl ester), carboxy-lower alkyl esters such as the carboxymethyl ester, nitrooxy-lower alkyl esters (such as the 4-nitro- oxybutyl ester), and the like. Preferred are the 5-alkyl substituted 2-arylaminophenyl- acetoxyacetic acids of formula la
CT
NH
R, Rs (1a)
R, R,
R, wherein R and R,.Rs have meaning as defined hereinabove for compounds of formula {; and pharmaceutically acceptable salts thereof.
Pharmaceutically acceptable salts represent metal salts, such as alkaline metal salts, e.g. . sodium, potassium, magnesium or calcium salts, as well as ammonium salts, which are formed e.g. with ammonia and mono- or di-alkylamines, such as diethylammonium salts, and . with amino acids, such as arginine and histidine salts.
The compound 5-methyl-2-(2'-chloro-6’-fluoro-anilino)-phenyl acetic acid, as well as its . pharmaceutically acceptable salts, is an especially useful COX-2 inhibitor for use in the present invention.
Therefore, the present invention relates to a method for the prevention or treatment of pre- malignant colon lesions or a colon cancer, or other malignacy, in a mammal, which comprises treating the mammal concurrently with a combination of (a) a selective COX-2 inhibitor and (b) a VEGF inhibitor.
Furthermore, the present invention relates to a method for the prevention or treatment of pre-malignant colon lesions or a colon cancer or other malignancy in a mammal, which comprises treating the mammal concurrently with a combination of (a) a selective COX-2 inhibitor of the formula (I) wherein R is methyl or ethyl; R, is chloro or fluoro; R; is hydrogen or fluoro; R; is hydrogen, fluoro, chloro, methyl, ethyl, methoxy, ethoxy or hydroxy, R, is hydrogen or fluoro; and Rs is chloro, fluoro, trifluoromethyl or methyl; pharmaceutically acceptable salts or solvates thereof; and pharmaceutically acceptable prodrug esters thereof; and (b) at least one compound selected from the group consisting of an MIA, an
EGFR inhibitor and a VEGF inhibitor.
In particular, the present invention relates to a combination which comprises (a) a selective
COX-2 inhibitor and (b) a VEGF inhibitor, in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier; for simultaneous, separate or sequential use.
Moreover, the present invention relates to a combination which comprises (a) a selective
COX-2 inhibitor of the formula (I) wherein R is methyl or ethyl; R;, is chloro or fluoro; R, is hydrogen or fluoro; Rj is hydrogen, fluoro, chloro, methyl, ethyl, methoxy, ethoxy or hydroxy;
R. is hydrogen or fluoro; and Rs is chloro, fluoro, trifluoromethyl or methyl; pharmaceutically * acceptable salts or solvates thereof; and pharmaceutically acceptable prodrug esters thereof; and (b) at least one compound selected from the group consisting of an MIA, a non- ) covalent EGF inhibitor and a VEGF inhibitor, in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt and
. = 6 = optionally at least one pharmaceutically acceptable carrier; for simultaneous, separate or sequential use.
Preferred combinations are in particular those wherein , o the selective COX-2 inhibitor of the formula (I) is 5-methyl-2-(2’-chloro-6’-fluoro- anilino)-phenyl acetic acid or a pharmaceutically acceptable salt thereof, o the combination partner (b) is an microtubule interfering agent selected from colchicine, a podophyllotoxin, a taxane, a discodermolide compound, a vinca alkaloid or an epothilone, in particular from paclitaxel, docetaxel, epothilone B and (+)- discodermolide, : e (a) the COX-2 inhibitor is selected from the group consisting of 5-methyl-2-(2’-chloro- 6’-fluoro-anilino)-phenyl acetic acid, or a pharmaceutically acceptable salt thereof, and (b) is an VEGF inhibitor selected from the group consisting of 1-(4-chloroanilino)- 4-(4-pyridylmethyl)phthalazine, or a pharmaceutically acceptable salt therof,
The combinations disclosed herein are suitable in particular for the use in the treatment of a proliferative disease and for use in the prevention or treatment of pre-malignant colon lesions or colon cancer.
According to the present invention, a patient is treated, e.g., concurrently with a COX-2 inhibitor and at least one compound selected from the group consisting of an MIA, an EGFR inhibitor and a VEGF inhibiror in order to prevent or treat pre-malignant colon lesions, such as polyps, or colon cancer, or another malignancy each according to a dosage schedule that is appropriate for the individual agent. For example, the COX-2 inhibitor may be administered once or more daily and an MIA may be administered once daily, on alternate days or on some other schedule — as is appropriate for the MIA agent when used without the
COX-2 inhibitor. ]
MIA compounds are known and clinically used for the treatment of cancer. Such compounds include colchicine, podophyllotoxins, such as etoposide and teniposide, taxanes, such as paclitaxel and docetaxel, discodermolide compounds, which includes (+)-discodermolide and analogs and derivatives of (+)-discodermolide, vinca alkaloids, such as vinblastin, especially vinblastine sulfate, vincristine, especially vincristine sulfate, and vinorelbine, and epothilones, such as epothilones A, B, C and D, as well as analogs and derivatives thereof, for example , the compounds disclosed in WO 99/02514, particularly [1S-{1R, 3R(E), 7R, 10S, 11R, 12R, 16S]}-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[1 -methyl —2-(2-methyl-4-thiazolyl)ethenyl}- 4-aza-17-bicyclo[14.1.0}-heptadecane-5,9-dione (example 3). Vinblastine sulfate can be administered, e.g., in the form as it is marketed, e.g. under the trademark VINBLASTIN
R.P.™. Vincristine sulfate can be administered, e.g., in the form as it is marketed, e.g. under the trademark FARMISTIN™. Discodermolide can be obtained, e.g., as disclosed in U.S. patent nos. 4,939,168 and 5,618,487 to Harbor Branch Oceanographic Institute or by chemical synthesis as described, for example, in GB 2280677, WO 98/24429 and U.S. patent nos. 5,789605 and 6,031,133, which are here incorporated by reference. Etoposide can be administered, e.g., in the form as it is marketed, e.g. under the trademark
ETOPOPHOS™. Teniposide can be administered, e.g., in the form as it is marketed, e.g. under the trademark VM 26-BRISTOL™.
Discodermolide, as well as its analogs and derivatives, are especially useful MIA compounds. Discodermolide and its preparation are known in the art. The preparation of analogs and derivatives has also been reported in the literature.
Epothilones that can be used in the present invention are described by formula (il),
R 4 “% /»—R
HO 77] NN | N ww 3 A : wherein A represents O or NRy, wherein Ry is hydrogen or lower alkyl, R is hydrogen or
R lower alkyl, R’ is methyl, methoxy, ethoxy, amino, methylamino, dimethylamino or methylthio, and Z is O or a bond.
Unless stated otherwise, in the present disclosure organic radicals and compounds designated “lower” contain not more than 7, preferably not more than 4, carbon atoms.
A compound of formula Il wherein A represents O, R is hydrogen, R’ is methyl and Z is O is . known as epothilone A; a compound of formula Il wherein A represents O, R is methyl, R’ is methyl and Z is O is known as epothilone B; a compound of formula Il wherein A represents
O, Ris hydrogen, R’ is methyl and Z is a bond is known as epothilone C; a compound of formula Il wherein A represents O, R is methyl, R’ is methyl and Z is a bond is known as epothilone D.
Epothilone derivatives of formula Il wherein A represents O or NRy, wherein Ry is hydrogen or lower alkyl, R is hydrogen or lower alkyl, R’ is methyl and Z is O or a bond, and methods for the preparation of such epothilone derivatives are in particular generically and specifically disclosed in the patents and patent applications WO 93/10121, US 6,194,181, WO 98/25929,
WO 98/08849, WO 99/43653, WO 98/22461 and WO 00/31247 in each case in particular in the compound claims and the final products of the working examples, the subject-matter of which is hereby incorporated into the present application by reference to this publications.
Comprised are likewise the corresponding stereoisomers as well as the corresponding crystal modifications, e.g. solvates and polymorphs, which are disclosed therein. Epothilone derivatives of formula Il, especially epothilone B, can be administered as part of pharmaceutical compositions which are disclosed in WO 99/39694.
Epothilone derivatives of formula Il wherein A represents O or NRy, wherein Ry is hydrogen or lower alkyl, R is hydrogen or lower alkyl, R’ is methoxy, ethoxy, amino, methylamino, dimethylamino or methyithio, and Z is O or a bond, and methods for the preparation and administration of such epothilone derivatives are in particular generically and specifically disclosed in the patent application W099/67252, which is hereby incorporated by reference into the present application. Comprised are likewise the corresponding stereoisomers as well as the corresponding crystal modifications, e.g. solvates and polymorphs, which are disclosed therein. *
The transformation of epothilone B to the corresponding lactam is disclosed in Scheme 21 ’ (page 31, 32) and Example 3 of WO 99/02514 (pages 48 - 50). The transformation of a compound of formula Il which is different from epothilone B into the corresponding lactam can be accomplished analogously. Corresponding epothilone derivatives of formula ll wherein Ry is lower alkyl can be prepared by methods known in the art such as a reductive alkylation reaction starting from the epothilone derivative wherein Ry is hydrogen.
It is known that MIA compounds such as paclitaxel, discodermolide, colchicine and vinblastine increase levels of prostaglandin E2 through upregulation of COX-2. Without being bound to any particular hypothesis, it is postulated that this effect may partially counteract the antiproliferative effects of MIA compounds. Thus, enhancement of the anti- tumor activity of the MIA by inhibition of COX-2 may be basis for the improved effect observed when, according to the present invention, a COX-2 inhibitor is added to a cancer treatment regimen with a MIA. As an added benefit, the COX-2 inhibitor may help manage cancer-related pain and inflammation.
In one aspect, the present invention relates to a method for the prevention of treatment of pre-malignant colon lesions (e.g. polyps), and colon cancers and other malignancies in a mammal, preferably a human patient, which comprises treating the patient concurrently with a combination of (a) a COX-2 inhibitor of U.S. Patent No. 6,291,523 and (b) a MIA.
In addition to the prevention and treatment of pre-malignant colon lesions (e.g. polyps) and colon cancer, the inventive combination therapy has utility for the treatment of “other malignancies”, which is hereby defined as a malignancy that is suseptible to treatment with an MIA compound, for example, breast cancer, lung cancer, ovarian cancer, lymphoma, head and neck cancer and cancer of the esophagus, stomach, bladder, prostrate, uterus and cervix.
Most preferably, the present invention relates to a method for the prevention or treatment of pre-malignant colon lesions, colon cancer or another malignancy in a human patient, which comprises treating the patient concurrently with a combination of (a) a COX-2 inhinitor selected from the group consisting of 5-methyi-2-(2'-chioro-6’-fluoro-anilino)-phenyl acetic
J acid, or a pharmaceutically acceptable salt thereof, and (b) an MIA selected from the group consisting of colchicine, a podophyllotoxin, a taxane, a discodermolide compound, a vinca : alkaloid and an epothilone. Especially, the MIA is a taxane, an epothilone or a disco- dermolide compound, preferably the MIA is paclitaxel, docetaxel, epothilone B or (+)- discodermolide, especially (+)-discodermolide. In a specific embodiment, the inventive method is a method for the prevention or treatment of colon cancer. In another embodiment, the inventive method is a method for the treatment of other malignancies as described above.
Preferably, treatment using a COX-2 inhibitor within one of the preferred classes disclosed in ’
U.S. Patent No. 6,291,523 is combined with treatment using an MIA selected from colchicine, a podophyllotoxin, a taxane, a discodermolide compound, a vinca alkaloid or an epothilone. Preferably, the MIA is paclitaxel, docetaxel, epothilone B or discodermolide.
EGFR inhibitors and their use as agents for the treatment of cancer are also known in the art. Non-covalent EGFR inhibitors useful in the present invention especially include 7H- pyrrolo{2,3-d}pyrimidine derivatives, such as those described in U.S. Patent No. 6,140,332, which is here incorporated by reference. Salts and solvates of the 7H-pyrrolo{2,3- d}pyrimidine derivatives are included in the EGFR inhibitors useful in the present invention.
The compound (R)-4-(4-((1-phenylethyl)amino)-7H-pyrrolo(2,3-d)pyrimidin-6-yl)-phenol, or a pharmaceutically acceptable salt therof, is the preferred 7H-pyrrolo{2,3-d}pyrimidine derivative for use in the present invention.
Hence, in another aspect, the present invention relates to a method for the prevention of treatment of pre-malignant colon lesions (e.g. polyps) and colon cancers in a human patient, which comprises treating the patient concurrently with a combination of (a) a COX-2 inhibitor of U.S. Patent No. 6,291,523 and (b) a non-covalent EGFR inhibitor of U.S. Patent No. 6,140,332.
In one aspect, treatment using a COX-2 inhibitor within one of the preferred classes disclosed in U.S. Patent No. 6,291,523 is combined with treatment using an EGFR inhibitor within one of the preferred classes disclosed in U.S. Patent No. 6,140,332. in another aspect, treatment using a COX-2 inhibitor within one of the preferred classes ° disclosed in U.S. Patent No. 6,291,523 is combined with treatment using an EGFR inhibitor selected from the group consisting of (R)-4-(4-((1-phenylethyl)amino)-7H-pyrrolo(2,3- ) d)pyrimidin-6-yl)-phenol, or a pharmaceutically acceptable salt therof.
In a different aspect, treatment using a COX-2 inhibitor selected from the group consisting of 5-methyl-2-(2'-chloro-6’-fluoro-anilino)-phenyl acetic acid, or a pharmaceutically acceptable ) salt thereof, is combined with treatment using an EGFR inhibitor within one of the preferred classes disclosed in U.S. Patent No. 6,140,332.
In addition to the prevention and treatment of pre-malignant colon lesions (e.g. polyps) and colon cancer, the inventive combination therapy has utility for the treatment of “other malignancies”, which is hereby defined as a malignancy that is suseptible to treatment with an EGFR inhibitor, for example, breast cancer, lung cancer, ovarian cancer, lymphoma, head and neck cancer and cancer of the esophagus, stomach, bladder, prostrate, uterus and cervix.
According to the present invention, a patient is treated concurrently with a COX-2 inhibitor and an EGFR inhibitor in order to prevent or treat pre-malignant colon lesions, such as polyps, or colon cancer, or another malignancy, each according to a dosage schedule that is appropriate for the individual agent. For example, the COX-2 inhibitor may be administered once or more daily and the EGFR inhibitor may be administered once daily, on alternate days or on some other schedule.
VEGF inhibitors and their use for the treatment of cancer are known in the art. Important
VEGF inhibitors are the 4-pyridylmethyl-phthalazine derivatives that are described in U.S.
Patent No. 6,258,812, which is here incorporated by reference. In a particular embodiment, the 4-pyridylmethyl-phthalazine derivative is 1-(4-chloroanilino)-4-(4-pyridylmethyi)- phthalazine or a pharmaceutically acceptable salt thereof. Studies in humans have shown 1- (4-chloroanilino)-4-(4-pyridylmethyl)phthalazine to be well tolerated and to reduce tumor vascular permeability.
Thus, in one aspect, the present invention relates to a method for the prevention of treatment of solid tumors in a mammal, preferably a human patient, which comprises treating © the mammal concurrently with a combination of (a) a COX-2 inhibitor of U.S. Patent No. 6,291,523 and (b) 4-pyridylmethyl-phthalazine VEGF inhibitor of U.S. Patent No. 6,258,812
In a broader sense of the invention, the term VEGF inhibitor comprises all types of active ingredients, which decrease the activity of the VEGF, and which are especially selected from the group consisting of compounds which inhibit the VEGF receptor tyrosine kinase, compounds which inhibit a VEGF receptor and compounds binding to VEGF. Such an active ingredient, which decreases the activity of the VEGF, is in particular one of those compounds, proteins and monoclonal antibodies, which are generically and specifically disclosed in WO 98/35958, WO 00/09495, WO 00/27820, WO 00/59509, WO 98/11223,
WO 00/27819, WO 01/55114, WO 01/58899 and EP 0 769 947, which are described by M.
Prewett et al in Cancer Research 59 (1999) 5209-5218, by F. Yuan et al in Proc. Natl. Acad.
Sci. USA, vol. 93, pp. 14765-14770, December 1996, by Z. Zhu et al in Cancer Res. 58, 1998, 3209-3214, and by J. Mordenti et al in Toxicologic Pathology, Vol. 27, no. 1, pp 14-21, 1999, those which are generically and specifically disclosed in WO 00/37502 and WO 94/10202; and those which are described by M. S. O'Reilly et al, Cell 79, 1994, 315-328 (Angiostatin™) and by M. S. O'Reilly et al, Cell 88, 1997, 277-285 (Endostatin™), in each case in particular in the pharmaceutical preparations and the final products of the working examples, which are hereby incorporated into the present application by reference to this publications. Comprised are likewise the corresponding stereoisomers as well as the corresponding crystal modifications, e.g. solvates and polymorphs, which are disclosed therein. The compounds used as active ingredients in the combinations disclosed herein can be prepared and administered as described in the cited documents, respectively.
In one aspect, treatment using a COX-2 inhibitor within one of the preferred classes disclosed in U.S. Patent No. 6,291,523 is combined with treatment using an VEGF inhibitor within one of the preferred classes disclosed in U.S. Patent No. 6,258,812,
In another aspect, treatment using a COX-2 inhibitor within one of the preferred classes disclosed in U.S. Patent No. 6,291,523 is combined with treatment using an VEGF inhibitor selected from the group consisting of 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine, or a pharmaceutically acceptable salt therof.
In a different aspect, treatment using a COX-2 inhibitor selected from the group consisting of 5-methyl-2-(2"-chloro-6'-fluoro-anilino)-phenyl acetic acid, or a pharmaceutically acceptable ’ salt thereof, is combined with treatment using an VEGF inhibitor within one of the preferred classes disclosed in U.S. Patent No. 6,258,812. ’
In one aspect, the present invention relates to a method for the prevention or treatment of pre-malignant colon lesions or a colon cancer, as well as other malignancies, in a mammalian patient, especially a human patient, which comprises treating the patient concurrently with a combination of (a) a COX-2 inhibitor selected from the group consisting of 5-methyl-2-(2'-chloro-6’-fluoro-anilino)-phenyl acetic acid, or a pharmaceutically acceptable salt thereof, and (b) an VEGF inhibitor selected from the group consisting of 1-(4- chloroanilino)-4-(4-pyridylmethyl)phthalazine, or a pharmaceutically acceptable salt therof.
In a specific embodiment, the inventive method is a method for the prevention or treatment of colon cancer. In another embodiment, the inventive method is a method for the prevention or treatment of pre-malignant colon lesions.
In addition to the prevention and treatment of pre-malignant colon lesions (e.g. polyps) and colon cancer, the inventive combination therapy has utility for the treatment of “other malignancies”, which is hereby defined as a malignancy that is suseptible to treatment with an VEGF inhibitor, for example, breast cancer, lung cancer, ovarian cancer, lymphoma, head and neck cancer and cancer of the esophagus, stomach, bladder, prostate, uterus and cervix, especially prostate cancer.
According to the present invention, a patient is treated concurrently with a COX-2 inhibitor and an VEGF inhibitor in order to prevent or treat pre-malignant colon lesions, such as polyps, or colon cancer, or another malignancy, each according to a dosage schedule that is appropriate for the individual agent. For example, the COX-2 inhibitor may be administered once or more daily and the VEGF inhibitor may be administered once daily, on alternate days or on some other schedule.
The structure of the active agents identified by code nos., generic or trade names may be taken from the actual edition of the standard compendium “The Merck Index” or from databases, e.g. Patents International (e.g. IMS World Publications). The corresponding content thereof is hereby incorporated by reference.
The present invention further relates to “a combined preparation”, which, as used herein, } defines especially a “kit of parts” in the sense that the combination partners (a) and (b) as defined above can be dosed independently or by use of different fixed combinations with distinguished amounts of the combination partners (a) and (b), i.e., simultaneously or at different time points. The parts of the kit of parts can then, e.g., be administered simultaneously or chronologically staggered, that is at different time points and with equal or different time intervals for any part of the kit of parts. The ratio of the total amounts of the combination partner (a) to the combination partner (b) to be administered in the combined preparation can be varied, e.g. in order to cope with the needs of a patient sub-population to be treated or the needs of the single patient based on the severity of the diarrhea that the patient experiences.
The present invention especially relates to a combined preparation, in particular wherein the unit dosage forms are for oral administration, which comprises (a) one or more unit dosage forms of a COX-2 inhibitor and (b) one or more unit dosage forms of an MIA. The present invention especially relates to a combined preparation, which comprises (a) one or more unit dosage forms of a COX-2 inhinitor selected from the group consisting of 5-methyl-2-(2'- chloro-6'-fluoro-anilino)-phenyl acetic acid, or a pharmaceutically acceptable salt thereof, and (b) one or more unit dosage forms of an MIA, especially selected from the group consisting of colchicine, a podophyllotoxin, a taxane, a discodermolide compound, a vinca alkaloid and an epothilone. Preferably, the MIA is a taxane, an epothilone or a disco- dermolide compound, more preferably the MIA is paclitaxel, docetaxel, epothilone B or (+)- discodermolide, most preferably the MIA is (+)-discodermolide.
Furthermore, the present invention especially relates to a combined preparation, which comprises (a) one or more unit dosage forms of a COX-2 inhibitor and (b) one or more unit dosage forms of an EGFR inhibitor. The present invention especially relates to a combined preparation, which comprises (a) one or more unit dosage forms of a COX-2 inhinitor selected from the group consisting of 5-methyl-2-(2’-chloro-6'-fluoro-anilino)-phenyl acetic acid, or a pharmaceutically acceptable salt thereof, and (b) one or more unit dosage forms of an EGFR inhibitor selected from the group consisting of (R)-4-(4-((1-phenylethyl)amino)-7H- pyrrolo(2,3-d)pyrimidin-6-yl)-phenol, or a pharmaceutically acceptable salt therof.
Additionally, the present invention relates to a combined preparation which comprises (a) ) one or more unit dosage forms of a COX-2 inhibitor selected from the group consisting of 5- methyl-2-(2’-chloro-6'-fluoro-anilino)-phenyl acetic acid, or a pharmaceutically acceptable salt ) thereof, and (b) one or more unit dosage forms of an VEGF inhibitor selected from the group consisting of 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine, or a pharmaceutically acceptable salt therof, especially, a combined preparation wherein the unit dosage forms are ) for oral administration.
The combination partner (a) or (b) or a pharmaceutically acceptable salt thereof may also be used in form of a hydrate or other solvate.
A combination which comprises a combination which comprises (a) a selective cyclo- oxygenase-2 inhibitor of the formula (1) wherein R is methyl or ethyl; R, is chloro or fluoro; R; is hydrogen or fluoro; Rj is hydrogen, fluoro, chloro, methyl, ethyl, methoxy, ethoxy or hydroxy; R, is hydrogen or fluoro; and Rs is chloro, fluoro, trifluoromethyl or methyl; pharma- ceutically acceptable salts or solvates thereof; and pharmaceutically acceptable prodrug esters thereof; and (b) at least one compound selected from the group consisting of an MIA, an EGFR inhibitor and a VEGF inhibitor, in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier, will be referred to hereinafter as a COMBINATION OF THE INVENTION.
Suitable clinical studies are in particular randomized, double-blind, placebo-controlled, parallel studies in cancer patients with late stage disease, e.g. colon cancer. Such studies are, in particular, suitable to compare the effects of a monotherapy using the active ingredients and a therapy using a COMBINATION OF THE INVENTION, and to prove in particular the synergism of the active ingredients of the COMBINATIONS OF THE INVENTION. The primary endpoints in such studies can be the effect on pain scores, analgesic use, performance status, Quality of Life scores or time to progression of the disease. The radiologic evaluation of tumors in regular time periods, e.g. every 4, 6, 8 or 10 weeks, is a suitable approach to determine the effect of the COMBINATION OF THE INVENTION. In a suitable study design, patients are, for example, randomized in a double-blind fashion receiving a fixed dosage of a COX-2 inhibitor or a corresponding placebo in addition to treatment cycles employing a compound of formula il, e.g. epothilone B, wherein each cycle ) consists of 0.5, 1.0, 1.5, 2.0 or 2.5 mg/m’ epothilone B administered as a 5 minute bolus injection once a week for three weeks followed by one week of rest. Alternatively, the ) compound of formula Il can be administered once every three weeks. The minimum duration of such a study should be about 8 weeks.
It is one objective of this invention to provide a pharmaceutical composition comprising a quantity, which is therapeutically effective pre-malignant colon lesions or colon cancer or } other malignancy comprising the COMBINATION OF THE INVENTION. In this composition, the combination partners (a) and (b) can be administered together, one after the other or separately in one combined unit dosage form or in two separate unit dosage forms. The unit dosage form may also be a fixed combination.
When the combination partners employed in the COMBINATION OF THE INVENTION are applied in the form as marketed as single drugs, their dosage and mode of administration can take place in accordance with the information provided on the package insert of the respective marketed drug in order to result in the beneficial effect described herein, if not mentioned herein otherwise.
The effective dosage of each of the combination partners employed in the COMBINATION
OF THE INVENTION may vary depending on the particular compound or pharmaceutical composition employed, the mode of administration, the condition being treated, the severity of the condition being treated. Thus, the dosage regimen the COMBINATION OF THE
INVENTION is selected in accordance with a variety of factors including the route of administration and the renal and hepatic function of the patient. A physician, clinician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the single active ingredients required to prevent, counter or arrest the progress of the condition.
Optimal precision in achieving concentration of the active ingredients within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the active ingredients’ availability to target sites.
In particular, the present invention provides a commercial package comprising (a) a selective cyclooxygenase-2 inhibitor of the formula (I) wherein the radicals and symbols have the meaning as provided above and (b) at least one compound selected from the group consisting of a MIA, a non-covalent EGFR inhibitor and a VEGF inhibitor, together with instructions for simultaneous, separate or sequential use thereof in the treatment of a proliferative disease.
In the instance where the COX-2 inhibitor is 5-methyl-2-(2'-chloro-6’-fluoro-anilino)-phenyl acetic acid, or a pharmaceutically acceptable salt thereof, an appropriate dose is in the range from 100 to 1500 mg of 5-methyl-2-(2’-chloro-6'-fluoro-anilino)-phenyl acetic acid . daily, for example, 200-1000 mg/day, such as 200, 400, 500, 600, 800, 900 or 1000 mg/day, administered in one or two doses daily. Preferably, 5-methyl-2-(2'-chloro-6’-fluoro-anilino)- phenyl acetic acid, or a pharmaceutically acceptable salt thereof is administered as an oral pharmaceutal formulation in the form of a tablet, capsule or syrup.
In the instance where the EGFR inhibitor is (R)-4-(4-((1-phenylethyl)amino}-7H-pyrrolo(2,3- d)pyrimidin-6-yl)-phenol, or a pharmaceutically acceptable salt therof, a daily dose of (R)-4- (4-((1-phenylethyl)amino)-7H-pyrrolo(2,3-d)pyrimidin-6-yl)-phenol in the range from 50 to 2000 mg, for example 1000 mg, 1200 mg, 1500 mg and 2000 mg, is appropriate. lt is also possible to administer the above described daily dose efficaciously on a less than daily basis in order to reduce side effects, such as liver toxicity. For example, it is appropriate to administer (R)-4-(4-((1-phenylethyl)amino)-7H-pyrrolo(2,3-d)pyrimidin-6-yl)-phenol, or a pharmaceutically acceptable salt therof, according to a treatment regimen whereby over at least a three week period, the EGFR inhibitor is administered on only about 40% to about 71% of the days. For example, (R)-4-(4-((1-phenylethyl)amino)-7H-pyrrolo(2,3-d)pyrimidin- 6-yl)-phenol, or a pharmaceutically acceptable salt therof, is administered to the patient from three to five times in each seven day period for a period of three weeks or longer, such as three or four times a week on alternate days for a period of three weeks or longer or three times each week on alternate days, for example, on Monday, Wednesday and Friday of each week, for at least three weeks. The dosage regimen is carried out through at least three or more weeks, for example for 3, 4, 5, 6, 7 or 8 weeks.
In the instance where the VEGF inhibitor is 1-(4-chloroanilino)-4-(4-pyridylmethyl)- phthalazine, or a pharmaceutically acceptable salt therof, a daily dose of 1-(4-chloroanilino)- 4-(4-pyridyimethyl)phthalazine in the range from 50 to 2000 mg, for example 1000 mg, 1200 mg, 1500 mg and 2000 mg, is appropriate. It is also possible to administer the above described daily dose efficaciously on a less than daily basis in order to reduce side effects, such as liver toxicity. For example, it is appropriate to administer 1-(4-chloroanilino)-4-(4- i pyridyimethyl)phthalazine, or a pharmaceutically acceptable salt therof, according to a treatment regimen whereby over at least a three week period, the VEGF inhibitor is administered on only about 40% to about 71% of the days. For example, 1-(4-chloroanilino)- 4-(4-pyridylmethyl)phthalazine, or a pharmaceutically acceptable salt therof, is administered to the patient from three to five times in each seven day period for a period of three weeks or longer, such as three or four times a week on alternate days for a period of three weeks or longer or three times each week on alternate days, for example, on Monday, Wednesday and Friday of each week, for at least three weeks. The dosage regimen is carried out through at least three or more weeks, for example for 3, 4, 5, 6, 7 or 8 weeks.
As used herein, the expression “week” means seven consecutive days. Thus, a three week period is twenty-one consecutive days starting on any day of the calendar week. The day that the first dose is given is considered to be the first day of the week. Any discussion using calendar weeks is intended to be for illustrative purposes only.
Preferably, (R)-4-(4-((1-phenylethyl)amino)-7H-pyrrolo(2,3-d)pyrimidin-6-yl)-phenol, or a pharmaceutically acceptable salt therof, or a pharmaceutically acceptable salt thereof, is administered as an oral pharmaceutal formulation in the form of a tablet, capsule or syrup.
Preferably, 1-(4-chloroanilino)-4-(4-pyridyimethyl)phthalazine, or a pharmaceutically acceptable salt therof, or a pharmaceutically acceptable salt thereof, is administered as an oral pharmaceutal formulation in the form of a tablet, capsule or syrup.
Co Epothilone B is preferably administered in a dose which is calculated according to the formula (iil) single dose (mg/m2) = (0.1 toy) x N (my wherein N is the number of weeks between treatments and y is 6, wherein epothilone B is administered in more than one treatment cycle after an interval of one week to six weeks after the preceding treatment.
In one preferred embodiment of the invention, epothilone B is administered weekly in a dose that is between about 0.1 to 6 mg/m?, preferably between 0.1 and 3 mg/m?, e.g. 2.5 or 3.0 mg/m?, for three weeks after an interval of one to six weeks, especially an interval of one week, after the preceding treatment. In another embodiment of the invention said epothilone
B is preferably administered to a human every 18 to 24 days in a dose that is between about 0.3 and 12 mg/m®.
Etoposide phosphate may be administered to a human in a dosage range varying from about 25 to 115 mg/m°day, e.g. 56.8 or 113.6 mg/m°day. } Teniposide may be administered to a human in a dosage range varying from about 75 to 150 mg about every two weeks.
Paclitaxel may be administered to a human in a dosage range varying from about 50 to 300 mg/m*day.
Vinblastine may be administered to a human in a dosage range varying from about 1.5 to 10 mg/mZday.
Vincristine sulfate may be administered parenterally to a human in a dosage range varying from about 0.025 to 0.05 mg/kg body weight - week.
Vinorelbine may be administered to a human in a dosage range varying from about 10 to 50 mg/m’day.
Furthermore, the present invention pertains to the use of a combination which comprises (a) a selective cyclooxygenase-2 inhibitor, in particular a selective cyclooxygenase-2 inhibitor of the formula (I) wherein the radicals and symbols have the meanings as provided above or a pharmaceutically acceptable prodrug ester thereof, and (b) a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier; for the preparation of a medicament for the treatment of a proliferative disease, especially for the treatment of cancer of the prostate.
Moreover, the present invention pertains to the use of a combination which comprises (a) a ) selective cyclooxygenase-2 inhibitor, in particular a selective cyclooxygenase-2 inhibitor of the formula (I) wherein the radicals and symbols have the meanings as provided above or a pharmaceutically acceptable prodrug ester thereof, and (b) at least one compound selected from the group consisting of a microtubule interfering agent, a non-covalent epithelial growth factor receptor tyrosine protein kinase inhibitor and a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier; for the preparation of a medicament for the treatment of a proliferative disease, in particular for the prevention or treatment of pre- malignant colon lesions or colon cancer.
The following Examples illustrate the invention described above; they are not, however, intended to limit the scope of the invention in any way. The beneficial effects of the
COMBINATION OF THE INVENTION can also be determined by other test models known as such to the person skilled in the pertinent art.
Example 1: 5-methyl-2-(2’-chloro-6-fluoro-anilino)-phenyl acetic acid (“COX”) and (+)-discodermolide (“disco”) are tested as single agents and together as combination therapy in a mouse model of adenomatous polyposis for the prevention and treatment of intestinal polyps. (+)-Disco- dermolide is administered once intravenously to the mice at 15 mg/kg as a solution in 16.7%
Chremophor El, 8.3% ethanol, and 75% DSW. COX is administered in the feed mix at a concentration of125 ppm. The following results of duplicate experiments are observed:
DRUGS ! POLYPS 1 ANIMALS
Com- | Route | Regimen | Dose Mean | % % Body |Dead/ pound (mg/kg) Intestinal T/C Wt. Total
Polyp Count | | Change (# + SEM)
COX + | feed + | ad libitum + | 125 ppm+15] 80.3 | [o7disco iV. Once | mgkg | | | | ‘
) DRUGS POLYPS ANIMALS
Com- Regimen Dose Mean % |% Body Wt.| Dead § pound (mg/kg) Intestinal T/C Change /
Polyp Count Total (# + SEM)
COX + | feed + i.v. |ad libitum +| 125 ppm+15] 80.17 34 0/7 disco Once mg/kg
Both agents alone cause a statistically significant reduction in the number of newly formed intestinal polyps. The combination further reduces the number of new polyps to a level that is lower than either agent alone and that is statistically significant. Statistical evaluations are performed using a one tailed Student t-test and all p values are less than 0.01.
Example 2: 5-methyl-2-(2’-chloro-6’-fluoro-anilino)-phenyl acetic acid (“COX”) and (R)-4-(4-((1- phenylethyl)amino)-7H-pyrrolo(2,3-d)pyrimidin-6-yl)-phenol (“EGFR”) are tested as single agents and together as combination therapy in a mouse model of adenomatous polyposis for the prevention and treatment of intestinal polyps. EGFR is administered to the mice orally at 50 mg/kg, as a suspension in 0.5% carboxymethylcellulose, b.i.d., 5 days a week for three weeks. COX is administered in the feed mix at a concentration of125 ppm. The following results are observed in duplicate experiments:
Mean
Intestinal )
Polyp % Body
Com- Dose Count % Wi. Dead / pound Route Regimen (mg/kg) (#+ SEM) | T/C | Change | Total
I HR EON I 0
EGFR p.o., Sx/week 50 mg/kg 37 |-28x201]| 0/7 b.i.d.
COX feed + | ad libitum + | 125 ppm + 25 [-04+01| 0/7 + p.o., 5x/week 50 mg/kg
EGFR b.i.d.
Mean
Intestinal
Polyp % Body
Com- Dose Count % Wit. Dead / pound Regimen (mg/kg) (#+ SEM) | T/C | Change | Total oN ES BE
I a Ee Ea Ks Ea Cn
EGFR p.o., Sx/week 50 mg/kg 9x03 27 25+0.1 0/7 b.i.d.
COX + | teed + | ad libitum | 125 ppm + 6x02 18 |-0.7+02| 0/7 .
EGFR p.o., | +5xweek | 50 mg/kg b.i.d.
Both agents alone cause a statistically significant reduction in the number of newly formed intestinal polyps. The combination further reduces the number of new polyps to a level that is lower than either agent alone and that is statistically significant. Statistical evaluations are performed using a one tailed Student t-test and all p values are less than 0.001.
Example 3: 5-methyl-2-(2’-chloro-6’-fluoro-anilino)-phenyl acetic acid (“COX”) and 1-(4-chloroanilino)-4- (4-pyridylmethyl)phthalazine (“WEGFR”) are tested as single agents and together as combination therapy in a mouse model of adenomatous polyposis for the prevention and treatment of intestinal polyps. VEGFR is administered to the mice orally at 100 mg/kg, 5 times a week for three weeks. COX is administered in the feed mix at a concentration of 125 ppm. The following results are observed in duplicate experiments:
Mean
Intestinal
Polyp % Body Dead
Com- Dose Count Wit. / pound Regimen (mg/kg) (#2: SEM) { % T/C | Change Total
VEGF po | sume 100 mg/kg | 15+ 0.48 5.46 + 0.24
COX + | feed+ | ad libitum | 125 ppm + 910.24 5310.11 | 0/7
VEGF p.o. + 5x/week | 100 mg/kg
} Mean
Intestinal “
Polyp % Body | Dead
Com- Dose Count Wi. / pound | Route | Regimen (mg/kg) (#+ SEM) [{ % T/C | Change | Total ey By
EC a a Ke) I
COX + | feed + | adlibitum + | 125ppm+ | 8 +£0.19 1.0+013 | 0/7
VEGF | p.o. S5x/week 100 mg/kg
Both agents alone cause a statistically significant reduction in the number of newly formed intestinal polyps. The combination further reduces the number of new polyps to a level that is lower than either agent alone and that is statistically significant. Statistical evaluations are performed using a one tailed Student t-test and all p values are less than 0.001.
Example 4 5-methyl-2-(2'-chloro-6'-fluoro-anilino)-phenyl acetic acid (“COX") and 1-(4-chloroanilino)-4- (4-pyridylmethyl)phthalazine (“VEGFR”) are tested as single agents and together as combination therapy in a mouse model of prostrate cancer (orthoscopically implanted DU 145 prostate tumor cell line) for efficacy against established tumors. VEGFR is administered to the mice orally at 100 mg/kg, 5 times a week for three weeks, as a suspension in 0.5% microcrystalline cellulose, 0.1% Tween 80 in water. COX is administered in the feed mix at a concentration of 125 ppm. The following results are observed: )
Mean
N Tumor
Weight % Body
Com- Dose (mg + % Wt. Dead / pound Regimen (mg/kg) SEM) T/C Change Total
Control q.d. S5xweek 428 + 69 36+072 | 0/12 (CMC/
Tween/
H.0) cox | reed powder, daily Ex 343 + 52 oo | 49+ 1.28 | 1/12
VEGF po | q.d. 5xweek | 100 mg/kg | 243 £37 99+ 3.39 | 1/12
COX + | feed+ | adlibitum+ | 125ppm + | 134% 27 31 35+ 296 | 0/12
VEGF p.o. Sx/week 100 mg/kg
Claims (12)
1. A combination which comprises (a) a selective cyclooxygenase-2 inhibitor and (b) a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in which the active . ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier; for simultaneous, separate or sequential use.
2. A combination which comprises (a) a selective cyclooxygenase-2 inhibitor of the formula m R g CH,COOH R, Rs R; R, R, wherein R is methyl or ethyl; R, is chloro or fluoro; R; is hydrogen or fluoro; R; is hydrogen, fluoro, chloro, methyl, ethyl, methoxy, ethoxy or hydroxy; R, is hydrogen or fluoro; and Rs is chloro, fluoro, trifluoromethyl or methyl; pharmaceutically acceptable salts or solvates thereof; and pharmaceutically acceptable prodrug esters thereof; and (b) at least one compound selected from the group consisting of a microtubule interfering agent, a non-covalent epithelial growth factor receptor tyrosine protein kinase inhibitor and a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in which the active ingredients (a) and (b) are present in each case in free form or in the . form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier; for simultaneous, separate or sequential use. :
3. Combination according to claim 1 or 2 wherein the selective cyclooxygenase-2 inhibitor of the formula (1) is 5-methyl-2-(2'-chloro-6'-fluoro-anilino)-phenyl acetic acid or a pharma- ceutically acceptable salt thereof.
4. Combination according to claim 2 or 3 wherein the combination partner (b) is an microtubule interfering agent selected from colchicine, a podophyllotoxin, a taxane, a discodermolide compound, a vinca alkaloid or an epothilone.
5. Combination according to claim 4 wherein the microtubule interfering agent is paclitaxel, docetaxel, epothilone B or (+)-discodermolide.
6. Combination according to claim 1 or 2 wherein (a) the COX-2 inhibitor is selected from the group consisting of 5-methyl-2-(2’-chloro-6'-fluoro-anilino)-phenyl acetic acid, or a pharmaceutically acceptable salt thereof, and (b) an VEGF inhibitor is selected from the group consisting of 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine, or a pharmaceutically acceptable salt therof.
7. Combination according to any one of claims 1 to 6 for use in the treatment of a proliferative disease.
8. Combination according to any one of claims 1 to 6 for use in the prevention or treatment of pre-malignant colon lesions or colon cancer.
9. Use of a combination according to any one of claims 1 to 6 for the preparation of a medicament for the treatment of a proliferative disease.
10. Use of a combination according to any one of claims 1 to 6 for the preparation of a medicament for the prevention or treatment of pre-malignant colon lesions or colon cancer.
11. Use of a combination according to claim 6 for the preparation of a medicament for the ) treatment of cancer of the prostate.
12. Use of a selective cyclooxygenase-2 inhibitor of the formula (1)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34473401P | 2001-10-25 | 2001-10-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200402939B true ZA200402939B (en) | 2005-02-07 |
Family
ID=34589946
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200402939A ZA200402939B (en) | 2001-10-25 | 2004-04-16 | Combinations comprising a selective cyclooxygenase-2 inhibitor. |
Country Status (1)
Country | Link |
---|---|
ZA (1) | ZA200402939B (en) |
-
2004
- 2004-04-16 ZA ZA200402939A patent/ZA200402939B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20110046190A1 (en) | Combinations comprising a selective cyclooxygenase-2 inhibitor | |
US20060270665A1 (en) | Combination comprising an agent decreasing VEGF activity and an agent decreasing EGF activity | |
JP2015512425A (en) | Combination products with tyrosine kinase inhibitors and their use | |
US7723339B2 (en) | Combination comprising a signal transduction inhibitor and an epothilone derivative | |
MX2008016125A (en) | Organic compounds. | |
AU2007247112B2 (en) | Combination comprising an iron chelator and an anti-neoplastic agent and use thereof | |
AU2002308218A1 (en) | Combination comprising a signal transduction inhibitor and an epothilone derivative | |
ZA200402939B (en) | Combinations comprising a selective cyclooxygenase-2 inhibitor. | |
AU2002351784A1 (en) | Combinations comprising a selective cyclooxygenase-2 inhibitor | |
JP2003055208A (en) | Combination chemotherapy | |
TW200950789A (en) | Antitumor agent, kit and method of treating cancer | |
US20030139430A1 (en) | Use of organic compounds | |
CZ20032277A3 (en) | Combination of signal transmission inhibitor and epothilone derivative for treating proliferative diseases |